Patient and disease characteristics
Variable . | No. (%) of patients . |
---|---|
No. of patients | 1007 |
Patient age, y, range (median) | 1-75 (45) |
Sex (male/female) | 588 (58)/419 (42) |
De novo MDS | 771 (77) |
Secondary MDS | 236 (23) |
Antecedent disorders* | 228 (23) |
Prior therapy† | 374 (37) |
FAB/WHO classification | |
RA‡ | 377 (37.4) |
RCMD‡ | 82 (8.1) |
MDS-U | 25 (2.5) |
RARS | 15 (1.5) |
RAEB§ | 304 (30.2) |
RAEB-1 | 46 (4.5) |
RAEB-2 | 42 (4.2) |
RAEB-T | 91 (9.1) |
tAML | 113 (11.2) |
Cytogenetics | |
IPSS | |
Good | 434 (43.1) |
Intermediate | 182 (18.1) |
Poor | 304 (30.2) |
5-group | |
Very good | 13 (1.3) |
MK+/MK−/unknown | 0/13/0 |
Good | 440 (43.7) |
MK+/MK−/unknown | 0/440/0 |
Intermediate | 175 (17.4) |
MK+/MK−/unknown | 7/167/1 |
Poor | 148 (14.7) |
MK+/MK−/unknown | 60/88/0 |
Very poor | 97 (9.6) |
MK+/MK−/unknown | 89/8/0 |
Data incomplete | 134 (13.3) |
Variable . | No. (%) of patients . |
---|---|
No. of patients | 1007 |
Patient age, y, range (median) | 1-75 (45) |
Sex (male/female) | 588 (58)/419 (42) |
De novo MDS | 771 (77) |
Secondary MDS | 236 (23) |
Antecedent disorders* | 228 (23) |
Prior therapy† | 374 (37) |
FAB/WHO classification | |
RA‡ | 377 (37.4) |
RCMD‡ | 82 (8.1) |
MDS-U | 25 (2.5) |
RARS | 15 (1.5) |
RAEB§ | 304 (30.2) |
RAEB-1 | 46 (4.5) |
RAEB-2 | 42 (4.2) |
RAEB-T | 91 (9.1) |
tAML | 113 (11.2) |
Cytogenetics | |
IPSS | |
Good | 434 (43.1) |
Intermediate | 182 (18.1) |
Poor | 304 (30.2) |
5-group | |
Very good | 13 (1.3) |
MK+/MK−/unknown | 0/13/0 |
Good | 440 (43.7) |
MK+/MK−/unknown | 0/440/0 |
Intermediate | 175 (17.4) |
MK+/MK−/unknown | 7/167/1 |
Poor | 148 (14.7) |
MK+/MK−/unknown | 60/88/0 |
Very poor | 97 (9.6) |
MK+/MK−/unknown | 89/8/0 |
Data incomplete | 134 (13.3) |
MDS-U indicates myelodysplastic syndrome, unclassified.
Among these, 54 had aplastic anemia and 8 had Fanconi anemia or other constitutional marrow failure states; 20 had Crohn disease, juvenile rheumatoid arthritis, or other autoimmune disorders; 9 had myeloproliferative neoplasms that evolved to MDS, 56 had Hodgkin or non-Hodgkin lymphoma, and 5 had multiple myeloma. Seventeen had previously been treated for other lymphoid or myeloid leukemias and 57 for solid tumors; 4 had received solid organ transplants, 2 had been accidentally exposed to radiation, and in 4 patients the etiology could not be ascertained.
Unknown in 34.
WHO categories defined only in more recent patients; RA includes patients with RCMD transplanted in earlier years.
In 139 patients with RAEB (categorized by FAB), a breakdown into RAEB-1 and RAEB-2 was not possible.